Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)

NCT06656624 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
190
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators